Opens in a new tab

Global Regulatory Partners GK Appoints Mariam Davis as Vice President, Japan

Announcement

Tokyo, Japan – [ May 19, 2026] — Global Regulatory Partners GK (GRP) announced the appointment of Mariam Davis as Vice President, Japan, reinforcing the company’s long‑term commitment to the Japanese market and its continued expansion across Asia.

In her new role, Ms. Davis will lead GRP’s Japan operations, overseeing strategic growth, operational execution, and collaboration across regulatory affairs, quality, market access, and product launch activities. She will work closely with clients, partners, and regulatory authorities to support successful product development and approvals in Japan.

Ms. Davis brings extensive experience in global operations and international market development, with a strong track record of supporting complex regulatory programs and cross‑functional teams. Her leadership has played a key instrumental role in strengthening GRP’s local capabilities and supporting life‑science companies navigating the Japanese regulatory environment.

“Japan is a critical market for our clients and our global strategy,” said Dr. Suzan Davis, President and CEO of Global Regulatory Partners. “Mariam’s deep operational expertise, leadership, and understanding of both global and local regulatory requirements make her ideally positioned to lead our Japan organization and support our continued growth.”

Ms. Davis’s appointment reflects GRP’s focus on building strong local leadership to deliver integrated regulatory, quality, and market‑access solutions tailored to the needs of the Japanese market.

About Global Regulatory Partners
Global Regulatory Partners (GRP) is a global regulatory, clinical, quality, and safety services organization supporting pharmaceutical, biotechnology, medical device, and life science companies worldwide. Through its integrated MAH and market‑access platform, GRP helps clients navigate complex regulatory pathways and accelerate access to global markets.

Related News

  • Baqsimi® Nasal Powder Featured in the September 2026 Issue of Nikkei DI

    Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi® Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.
  • GRP JAPAN JOINS THE JAPAN RADIOPHARMACEUTICALS ASSOCIATION

    Tokyo, Japan — October 2026 — Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Japan Radiopharmaceuticals Association, effective October 2026. The membership marks an important step in GRP Japan’s continued expansion into the radiopharmaceutical and nuclear medicine sector, complementing the company’s established capabilities in pharmaceuticals, biologics, medical devices, and diagnostics. As a Marketing Authorization Holder (MAH) and local regulatory partner for international healthcare companies entering Japan, GRP Japan is expanding its capabilities to support the specialized regulatory, quality, importation, supply-chain, and lifecycle requirements associated with radiopharmaceutical products. Through its membership, GRP Japan looks forward to industry collaboration and to contributing its regulatory and market-access experience to the continued development of the sector in Japan.
  • Global Regulatory Partners to Exhibit at BioJapan  2026

    Global Regulatory Partners (GRP) is pleased to announce its participation in BioJapan  2026, where GRP will exhibit at Booth C-41 and participate in the event's international Partnering program. BioJapan  2026 is observing its 40th anniversary as the world’s longest running biotechnology event.  It is held together with concurrent events,Regenerative Medicine JAPAN, and healthTECH JAPAN, bringing together biotechnology, pharmaceuticals, regenerative medicine, digital health, academia, investors, service providers, and other life-science stakeholders from Japan and around the world.
  • Global Regulatory Partners Announces MHLW Approval of Pegfilgrastim Biosimilar in Japan

    Tokyo, Japan – August 25, 2026 – Global Regulatory Partners GK (GRP GK) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on August 24, 2026, for Pegfilgrastim BS Subcutaneous Injection 3.6 mg 「GRP」, a pegfilgrastim biosimilar indicated for the prevention of febrile neutropenia associated with cancer chemotherapy.